The Quality and Outcomes Framework (QOF) is a key component of the NHS contract for general practitioners (GPs) in the UK, designed to incentivise and reward high-quality care for patients. Introduced in 2004 as part of the new GMS contract, QOF aimed to improve the quality of healthcare by linking financial rewards to clinical outcomes, patient satisfaction, and practice management.
The development of QOF stemmed from the need for a systematic and transparent approach to measure the quality of services provided by GPs. Prior to its introduction, the quality of care in general practice was largely unmeasured, making it difficult to assess performance and implement improvements. The QOF framework aimed to address this by setting out clear, evidence-based targets across a wide range of clinical areas.
Key Milestones:
2004: The QOF was introduced as part of the new General Medical Services (GMS) contract. It included a set of indicators across four domains: clinical, organisational, patient experience, and patient satisfaction. Practices could earn points by meeting these targets, with financial incentives tied to their performance.
2006: The first significant review of QOF led to the introduction of new indicators, reflecting emerging healthcare priorities. Over time, the framework continued to evolve, with updates to clinical standards, the addition of new disease areas, and changes to the weighting of points.
2014: A significant overhaul of the QOF occurred, with a focus on reducing the burden of reporting and streamlining the framework. Some indicators were retired, while new ones were added to reflect current health priorities, such as mental health, dementia care, and cardiovascular risk management.
2020: The introduction of the ‘COVID-19 Emergency QOF’ saw temporary changes to the framework, ensuring that general practice could remain adaptable during the pandemic. This period marked a shift towards more flexible measures, with an emphasis on remote consultations and innovative service delivery models.
How QOF Works:
QOF assigns points to various clinical and organisational indicators, with the total points determining the financial reward a practice receives. The clinical domain covers conditions such as diabetes, asthma, hypertension, and chronic obstructive pulmonary disease (COPD), among others. These indicators are based on national guidelines and aim to promote evidence-based best practices.
The patient experience domain includes measures of patient satisfaction, ensuring that practices focus not only on clinical outcomes but also on the quality of patient care. The organisational domain encourages practices to implement systems and processes that support high-quality care, such as maintaining electronic health records, improving accessibility, and engaging in continuous staff training.
Impact and Criticism:
While QOF has undoubtedly led to significant improvements in the quality of care in many areas of general practice, it has not been without its critics. Some argue that the financial incentives can lead to a focus on easily measurable outcomes at the expense of more holistic patient care. Others point out that the system can be bureaucratic and may not always reflect the complexities of patient care.
However, despite these criticisms, QOF has played a crucial role in shaping the delivery of primary care in the UK. It has encouraged practices to focus on quality improvement, provided a framework for measuring clinical performance, and incentivised GPs to provide evidence-based care.
| Indicator | What it Measures | Thresholds | Points | Replaces | |
|---|---|---|---|---|---|
| DM037 | All 8 NICE diabetes care processes annually | 40–90% | 10 | DM012 | |
| HF009 | 4‑pillar therapy in HFrEF | 20–50% | 12 | HF003, HF006 | |
| OB004 | Referral to structured weight management within 90 days | 10–30% | 5 | WM ES | |
| OB005 | Shared decision‑making + pharmacotherapy (tirzepatide) | 50–80% | 13 | WM ES | |
| CD001 | BP control <140/90 (CVD combined), age ≤79, no frailty | 40–90% | 41 | CHD015, CHD016, STIA014, STIA015 | |
| CD002 | Second BP threshold for same cohort | 46–90% | 20 | Same as above |
| Indicator | Domain | Description | Thresholds | Points |
|---|---|---|---|---|
| AF006 | AF | AF with CHADS₂‑VASc ≥2 on anticoagulation | 40–70% | 12 |
| AF007 | AF | AF with CHADS₂‑VASc ≥2 with anticoagulation contraindication recorded | 40–90% | 17 |
| AST006 | AST | Annual asthma review | 50–90% | 20 |
| AST007 | AST | Personalised asthma action plan | 40–77% | 25 |
| BP002 | BP | Adults with BP recorded in last 5 years | 50–90% | 41 |
| CD001 | CD | CVD patients ≤79, no frailty, BP <140/90 | 40–90% | 41 |
| CD002 | CD | Same cohort achieving second BP threshold | 46–90% | 20 |
| CHD005 | CHD | CHD patients with BP ≤140/90 | 40–77% | 17 |
| CHD014 | CHD | CHD patients with cholesterol ≤5 mmol/L | 40–75% | 12 |
| CHOL002 | CHOL | CVD patients on high‑intensity statin | 40–90% | 14 |
| CHOL003 | CHOL | CVD patients achieving ≥40% non‑HDL reduction | 40–77% | 12 |
| CHOL004 | CHOL | Familial hypercholesterolaemia on optimal therapy | 40–90% | 10 |
| COPD008 | COPD | Annual COPD review | 50–90% | 20 |
| COPD010 | COPD | MRC dyspnoea score recorded | 40–90% | 25 |
| CS005 | CS | Cervical screening uptake | 45–80% | 22 |
| DEM004 | DEM | Annual dementia face‑to‑face review | 35–70% | 39 |
| DM006 | DM | Diabetes BP ≤140/80 | 40–77% | 10 |
| DM007 | DM | Diabetes cholesterol ≤5 mmol/L | 40–75% | 6 |
| DM014 | DM | HbA1c ≤58 mmol/mol | 40–77% | 17 |
| DM015 | DM | HbA1c ≤75 mmol/mol | 40–85% | 10 |
| DM017 | DM | Albuminuria treated with ACEi/ARB | 40–90% | 14 |
| DM018 | DM | Foot risk classification | 40–90% | 10 |
| DM019 | DM | BMI recorded | 40–90% | 6 |
| DM020 | DM | Smoking status recorded | 40–90% | 6 |
| DM021 | DM | Smoking cessation advice | 40–90% | 6 |
| DM037 | DM | All 8 NICE diabetes care processes | 40–90% | 10 |
| HF008 | HF | HFrEF on ACEi/ARB/ARNI + beta‑blocker | 40–77% | 17 |
| HF009 | HF | HFrEF on all 4 pillars (ACEi/ARB/ARNI + BB + MRA + SGLT2i) | 20–50% | 12 |
| HYP008 | HYP | Hypertension BP ≤140/90 | 40–77% | 41 |
| MH021 | MH | Annual physical health check | 40–90% | 30 |
| MH022 | MH | BMI recorded | 40–90% | 8 |
| NDH002 | NDH | HbA1c or FPG in last 12 months | 40–90% | 18 |
| OB003 | OB | BMI recorded | 40–90% | 5 |
| OB004 | OB | Referral to weight‑management within 90 days | 10–30% | 5 |
| OB005 | OB | Shared decision‑making + pharmacotherapy | 50–80% | 13 |
| SMOK002 | SMOK | Smoking status recorded | 50–90% | 25 |
| SMOK004 | SMOK | Smoking cessation advice | 40–90% | 49 |
| STIA010 | STIA | Stroke/TIA BP ≤140/90 | 40–77% | 17 |
| STIA011 | STIA | Stroke/TIA cholesterol ≤5 mmol/L | 40–75% | 12 |
| VI001 | VI | 6‑in‑1 childhood immunisation | 89–96% | 18 |
| VI002 | VI | MMR1 uptake | 89–96% | 18 |
| VI003 | VI | MMR2 uptake | 86–96% | 18 |
| VI004 | VI | Pre‑school booster uptake | 86–96% | 10 |